Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 100 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,273,778 | +776.3% | 417,207 | +991.8% | 0.00% | – |
Q2 2023 | $259,467 | -83.5% | 38,213 | -87.9% | 0.00% | – |
Q1 2023 | $1,577,198 | -66.5% | 314,810 | -67.4% | 0.00% | -100.0% |
Q4 2022 | $4,708,326 | +128.0% | 964,821 | +573.5% | 0.00% | – |
Q3 2022 | $2,065,000 | +51.2% | 143,260 | +58.6% | 0.00% | – |
Q2 2022 | $1,366,000 | -44.5% | 90,300 | -56.4% | 0.00% | – |
Q1 2022 | $2,460,000 | +20.7% | 207,027 | +64.7% | 0.00% | – |
Q4 2021 | $2,038,000 | -38.2% | 125,698 | +8.7% | 0.00% | -100.0% |
Q3 2021 | $3,300,000 | -44.3% | 115,615 | -34.0% | 0.00% | 0.0% |
Q2 2021 | $5,921,000 | +114.2% | 175,185 | +91.7% | 0.00% | 0.0% |
Q1 2021 | $2,764,000 | -51.7% | 91,395 | -20.8% | 0.00% | 0.0% |
Q4 2020 | $5,717,000 | +1524.1% | 115,469 | +1159.5% | 0.00% | – |
Q3 2020 | $352,000 | -37.3% | 9,168 | -29.5% | 0.00% | – |
Q2 2020 | $561,000 | -43.3% | 13,000 | -65.7% | 0.00% | – |
Q1 2020 | $990,000 | -54.9% | 37,913 | -46.1% | 0.00% | -100.0% |
Q4 2019 | $2,197,000 | – | 70,328 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 191,176 | $1,041,909 | 4.24% |
Sofinnova Investments, Inc. | 2,194,278 | $11,958,815 | 0.75% |
DENALI ADVISORS LLC | 85,900 | $468,155 | 0.16% |
Polar Capital Holdings Plc | 2,103,298 | $11,462,974 | 0.08% |
Soleus Capital Management, L.P. | 157,182 | $856,642 | 0.08% |
GSA CAPITAL PARTNERS LLP | 137,299 | $748 | 0.06% |
Caligan Partners LP | 23,321 | $127,099 | 0.06% |
Corton Capital Inc. | 12,244 | $66,730 | 0.03% |
RICE HALL JAMES & ASSOCIATES, LLC | 91,249 | $497,307 | 0.03% |
CIM INVESTMENT MANAGEMENT INC | 15,313 | $83,456 | 0.03% |